Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML.

Debbie C Strachan¹, Christine J Gu¹, Ryosuke Kita¹, Erica K Anderson¹, Michelle A Richardson¹, George Yam¹, Graham Pimm¹, Jordan Roselli¹, Alyssa Schweickert¹, Maci Terrell², Raushan Rashid², Alan K Gonzalez², Hailey H Oviedo², Michelle C Alozie², Tamilini Ilangovan², Andrea N Marcogliese³, Hiroomi Tada¹, Marianne T Santaguida¹, Alexandra M Stevens²

¹Notable Labs, Foster City, CA 94404, USA.

²Division of Pediatric Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.

³Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA.

PubMed PMC DOI PDF

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease that accounts for ~20% of all childhood leukemias, and more than 40% of children with AML relapse within three years of diagnosis. Although recent efforts have focused on developing a precise medicine-based approach towards treating AML in adults, there remains a critical gap in therapies designed specifically for children. Here, we present e…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.